Finance Watch: US, Hong Kong IPOs Are Hot, But Sirnaomics Stays Private
The US- And China-Based Firm Raised A $105m Series E Round
Executive Summary
Private Company Edition: Sirnaomics planned to go public after its series D, but its new venture capital does not prevent it from doing so in the near term. Also, Vida Ventures and Novalis Biotech raised new VC funds to back start-ups and ArriVent launched with up to $150m in series A cash.
You may also be interested in...
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
Deal Watch: Sanofi Offloads Established Products, Lilly Testing 3D-Printed Drugs
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.
Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.